Terms: = Germ cell tumor AND PIK3R1, P27986, 5295, ENSG00000145675, p85-ALPHA, GRB1
56 results:
1. Clinicopathological analysis of rosette-forming glioneuronal tumors.
Liu J; Lin F; Sun Y; Liu X
Diagn Pathol; 2024 Feb; 19(1):39. PubMed ID: 38388383
[TBL] [Abstract] [Full Text] [Related]
2. A Novel Type of IDH-wildtype Glioma Characterized by Gliomatosis Cerebri-like Growth Pattern, TERT Promoter Mutation, and Distinct Epigenetic Profile.
Muench A; Teichmann D; Spille D; Kuzman P; Perez E; May SA; Mueller WC; Kombos T; Nazari-Dehkordi S; Onken J; Vajkoczy P; Ntoulias G; Bettencourt C; von Deimling A; Paulus W; Heppner FL; Koch A; Capper D; Kaul D; Thomas C; Schweizer L
Am J Surg Pathol; 2023 Dec; 47(12):1364-1375. PubMed ID: 37737691
[TBL] [Abstract] [Full Text] [Related]
3. Novel insight into histological and molecular astrocytoma, IDH-mutant, Grade 4 by the updated WHO classification of central nervous system tumors.
Chen W; Guo S; Wang Y; Shi Y; Guo X; Liu D; Li Y; Wang Y; Xing H; Xia Y; Li J; Wu J; Liang T; Wang H; Liu Q; Jin S; Qu T; Li H; Yang T; Zhang K; Wang Y; Ma W
Cancer Med; 2023 Sep; 12(18):18666-18678. PubMed ID: 37667984
[TBL] [Abstract] [Full Text] [Related]
4. ROS1 Alterations as a Potential Driver of Gliomas in Infant, Pediatric, and Adult Patients.
Meredith DM; Cooley LD; Dubuc A; Morrissette J; Sussman RT; Nasrallah MP; Rathbun P; Yap KL; Wadhwani N; Bao L; Wolff DJ; Ida C; Sukhanova M; Horbinski C; Jennings LJ; Farooqi M; Gener M; Ginn K; Kam KL; Sasaki K; Kanagal-Shamanna R; Alexandrescu S; Brat D; Lu X
Mod Pathol; 2023 Nov; 36(11):100294. PubMed ID: 37532182
[TBL] [Abstract] [Full Text] [Related]
5. A comprehensive genomic study of 390 H3F3A-mutant pediatric and adult diffuse high-grade gliomas, CNS WHO grade 4.
Williams EA; Brastianos PK; Wakimoto H; Zolal A; Filbin MG; Cahill DP; Santagata S; Juratli TA
Acta Neuropathol; 2023 Sep; 146(3):515-525. PubMed ID: 37524847
[TBL] [Abstract] [Full Text] [Related]
6. GDPD5 Related to Lipid Metabolism Is a Potential Prognostic Biomarker in Neuroblastoma.
Luo T; Peng J; Li Q; Zhang Y; Huang Y; Xu L; Yang G; Tan D; Zhang Q; Tan Y
Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430219
[TBL] [Abstract] [Full Text] [Related]
7. Molecular Evidence for Epithelial Origin of Mixed Ovarian Epithelial-germ cell Neoplasms: Report of 2 Cases and Review of Literature.
Hall KC; Post MD; Alldredge J; Aisner DL; Berning A
Int J Gynecol Pathol; 2023 Jul; 42(4):403-413. PubMed ID: 36305517
[TBL] [Abstract] [Full Text] [Related]
8. Pathway-based approach reveals differential sensitivity to E2F1 inhibition in glioblastoma.
Alvarado AG; Tessema K; Muthukrishnan SD; Sober M; Kawaguchi R; Laks DR; Bhaduri A; Swarup V; Nathanson DA; Geschwind DH; Goldman SA; Kornblum HI
Cancer Res Commun; 2022 Sep; 2(9):1049-1060. PubMed ID: 36213002
[TBL] [Abstract] [Full Text] [Related]
9. [Diffuse midline gliomas with H3K27 alteration in children: a clinicopathological analysis of forty-one cases].
Li J; Ma YY; Feng J; Zhao D; Ding F; Tian L; Chen R; Zhao R
Zhonghua Bing Li Xue Za Zhi; 2022 Apr; 51(4):319-325. PubMed ID: 35359043
[No Abstract] [Full Text] [Related]
10. Rosette-forming glioneuronal tumours are midline, FGFR1-mutated tumours.
Appay R; Bielle F; Sievers P; Barets D; Fina F; Boutonnat J; Adam C; Gauchotte G; Godfraind C; Lhermitte B; Maurage CA; Meyronet D; Mokhtari K; Rousseau A; Tauziède-Espariat A; Tortel MC; Uro-Coste E; Burel-Vandenbos F; Chotard G; Pesce F; Varlet P; Colin C; Figarella-Branger D
Neuropathol Appl Neurobiol; 2022 Aug; 48(5):e12813. PubMed ID: 35293634
[TBL] [Abstract] [Full Text] [Related]
11. Rosette-Forming Glioneuronal tumor in the Pineal Region: A Series of 6 Cases and Literature Review.
Lin CC; Mansukhani MM; Bruce JN; Canoll P; Zanazzi G
J Neuropathol Exp Neurol; 2021 Oct; 80(10):933-943. PubMed ID: 34498065
[TBL] [Abstract] [Full Text] [Related]
12. Promising potential of boron compounds against Glioblastoma: In Vitro antioxidant, anti-inflammatory and anticancer studies.
Turkez H; Arslan ME; Tatar A; Mardinoglu A
Neurochem Int; 2021 Oct; 149():105137. PubMed ID: 34293392
[TBL] [Abstract] [Full Text] [Related]
13. PET/CT using
Liu D; Cheng G; Ma X; Wang S; Zhao X; Zhang W; Yang W; Wang J
J Neuroimaging; 2021 Jul; 31(4):733-742. PubMed ID: 34021667
[TBL] [Abstract] [Full Text] [Related]
14. Environmental and sex-specific molecular signatures of glioma causation.
Claus EB; Cannataro VL; Gaffney SG; Townsend JP
Neuro Oncol; 2022 Jan; 24(1):29-36. PubMed ID: 33942853
[TBL] [Abstract] [Full Text] [Related]
15. Diverse mechanisms activate the PI 3-kinase/mTOR pathway in melanomas: implications for the use of PI 3-kinase inhibitors to overcome resistance to inhibitors of BRAF and MEK.
Tran KB; Kolekar S; Jabed A; Jaynes P; Shih JH; Wang Q; Flanagan JU; Rewcastle GW; Baguley BC; Shepherd PR
BMC Cancer; 2021 Feb; 21(1):136. PubMed ID: 33549048
[TBL] [Abstract] [Full Text] [Related]
16. Drug repurposing using transcriptome sequencing and virtual drug screening in a patient with glioblastoma.
Saeed MEM; Kadioglu O; Greten HJ; Yildirim A; Mayr K; Wenz F; Giordano FA; Efferth T
Invest New Drugs; 2021 Jun; 39(3):670-685. PubMed ID: 33313992
[TBL] [Abstract] [Full Text] [Related]
17. Comprehensive analysis of diverse low-grade neuroepithelial tumors with FGFR1 alterations reveals a distinct molecular signature of rosette-forming glioneuronal tumor.
Lucas CG; Gupta R; Doo P; Lee JC; Cadwell CR; Ramani B; Hofmann JW; Sloan EA; Kleinschmidt-DeMasters BK; Lee HS; Wood MD; Grafe M; Born D; Vogel H; Salamat S; Puccetti D; Scharnhorst D; Samuel D; Cooney T; Cham E; Jin LW; Khatib Z; Maher O; Chamyan G; Brathwaite C; Bannykh S; Mueller S; Kline CN; Banerjee A; Reddy A; Taylor JW; Clarke JL; Oberheim Bush NA; Butowski N; Gupta N; Auguste KI; Sun PP; Roland JL; Raffel C; Aghi MK; Theodosopoulos P; Chang E; Hervey-Jumper S; Phillips JJ; Pekmezci M; Bollen AW; Tihan T; Chang S; Berger MS; Perry A; Solomon DA
Acta Neuropathol Commun; 2020 Aug; 8(1):151. PubMed ID: 32859279
[TBL] [Abstract] [Full Text] [Related]
18. Genetic Profiling of Advanced Melanoma: Candidate Mutations for Predicting Sensitivity and Resistance to Targeted Therapy.
Olbryt M; Pigłowski W; Rajczykowski M; Pfeifer A; Student S; Fiszer-Kierzkowska A
Target Oncol; 2020 Feb; 15(1):101-113. PubMed ID: 31980996
[TBL] [Abstract] [Full Text] [Related]
19. Comparative proteogenomic characterization of glioblastoma.
Asif S; Fatima R; Krc R; Bennett J; Raza S
CNS Oncol; 2019 Jun; 8(2):CNS37. PubMed ID: 31290679
[No Abstract] [Full Text] [Related]
20. The Small GTPase ARF6 Activates PI3K in Melanoma to Induce a Prometastatic State.
Yoo JH; Brady SW; Acosta-Alvarez L; Rogers A; Peng J; Sorensen LK; Wolff RK; Mleynek T; Shin D; Rich CP; Kircher DA; Bild A; Odelberg SJ; Li DY; Holmen SL; Grossmann AH
Cancer Res; 2019 Jun; 79(11):2892-2908. PubMed ID: 31048499
[TBL] [Abstract] [Full Text] [Related]
[Next]
